

Bitte beachten Sie: Dieses Dokument wurde automatisch erstellt und ist kein Ersatz für das Originaldokument des Herstellers.

Product Datasheet

Recombinant 2019-nCoV S1 Protein EBT-EPT025

Artikelname	Recombinant 2019-nCoV S1 Protein
Artikelnummer	EBT-EPT025
Hersteller Artikelnummer	EPT025
Alternativnummer	EBT-EPT025-50
Hersteller	ELK Biotechnology
Kategorie	Proteine/Peptide
Produktbeschreibung	Recombinant SARS-CoV-2 S1 Protein is produced by our Mammalian expression system and the target gene encoding Gln14-Arg685 is expressed....
Molekulargewicht	Molecular weight: 78.3kDa. Apparent molecular weight: 100-130kDa, reducing conditions
UniProt	QHD43416.1
Reinheit	Greater than 95% as determined by reducing SDS-PAGE.

Anwendungsbeschreibung

Biological activity: Immobilized 2019-nCoV S1 Protein(CatDRA35) at 2µg/ml (100 µl/well) can bind Human ACE-2-Fc(CatC05Y). The ED50 of Human ACE-2-Fc(CatC05Y) is 15-150 ng/ml. Background: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. Its been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity